It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...

In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.  | In a remarkable turnaround, ...

Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...

Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound ...

Novo Nordisk has made Omnicom the agency of record for U.S. media buying, ending the drugmaker’s six-year partnership with ...

After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton ...

AstraZeneca and CSPC Pharmaceutical are strengthening their partnership by establishing a new biologics manufacturing joint ...

Despite a major curveball thrown by the FDA earlier this year, Moderna has managed to strike true with a U.S. approval for its mRNA-based influenza vaccine.  | Despite a major curveball thrown by the ...

Galderma Laboratories has landed a blow on Sanofi in its multi-case advertising row, driving the French drugmaker to change ...

News of the unconfirmed deal talks drew major investor pushback on AZ’s side, with the British drugmaker’s stock sliding nearly 9% following the Financial Times report. The company’s London-listed ...

In his first earnings call just days after becoming Sarepta Therapeutics' CEO, Michael Severino recognized that the rare ...

Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company ...